NewStem Ltd., a bio-platform company, today announced a collaboration with the MSK Innovation Hub to further optimize and validate NewStem’s bioinformatics-based software as a medical device diagnostic platform.

Bio-Platform NewStem Ltd today announced the filing of a pre-submission to the FDA for a De Novo Request and an in vitro diagnostic device (IVDD) for EMA for their NewStem Software Diagnostic Device. The announcement followed the company's graduation from Illumina's Accelerator 3rd funding cycle in March 2022.

NovelStem International Corp., a biotechnology company focused on the stem cell-based technology platform developed by 30%-owned Israel-based, NewStem, Ltd., announced that NewStem was selected by Illumina for its global Illumina Accelerator. Under the agreement, NewStem is entitled to a match funding for new capital of up to $5.5 million within 18 months. 

Illumina, Inc. has selected NewStem as one of seven new genomics companies to join the third global funding cycle of Illumina Accelerator. NewStem Ltd. , a cancer therapeutics and diagnostics company from Israel, is developing genetic-based products utilizing a proprietary haploid human embryonic stem cells library of mutations.

NovelStem International Corp., a biotechnology company focused on its stem cell-based technology platform, developed by Israel-based affiliate, NewStem Ltd., announced two new collaborations to apply NewStem’s technology platform, one to research a potential cancer immunotherapy drug and another to research genes responsible for COVID-19. NovelStem also announced the identification and completion of analysis of resistance to a dozen standard-of-care anti-cancer treatments.

NovelStem International Corp., a biotechnology company focused on stem-cell-based diagnostic technology to aid the selection of cancer therapeutic agents being developed by its Israel-based affiliate, NewStem Ltd., today announced it has completed a $1 million follow-on investment in NewStem, increasing its ownership in NewStem to 27.3% from 20%.

NewStem Ltd., a Jerusalem-based biotech with a novel precision-medicine technology that can increase chemotherapy’s effectiveness, today announced a $4 million seed financing from a publicly-traded US-based company to be named NovelStem International Corp. NewStem is a spinoff of Yissum, The Technology Transfer Company of The Hebrew University.

Hollywood Media Corp. announced the strategic transformation of the Company, its management and Board through an initial $2 million investment in Jerusalem, Israel-based NewStem Ltd. and a refocusing of HMC on the substantial commercial potential of NewStem’s novel diagnostic technology which can predict patients’ resistance to chemotherapy allowing for better, targeted cancer treatments and the potential to reduce resistance to chemotherapy. Drug resistance is a major cause of treatment failure in cancer chemotherapy, and currently it is only recognized after the first course of treatment has been completed. In nearly 50% of all cancer cases, resistance to chemotherapy already exists in the tumors before initiation of the treatment.